Antisense targeting in cell culture with radiolabeled DNAs —a brief review of recent progress—
The promise of antisense targeting that any tissue with a unique genetic expression can be specifically localized with radioactivity in the living subject is the holy grail that drives this research today. If antisense targeting were to achieve even a fraction of its promise, the results could well lead a revolution in diagnostic nuclear medicine. Despite its obvious complexities, antisense targeting with radiolabeled oligomers such as DNA is making considerable progress in cell culture. As is documented in this brief review, evidence is becoming overwhelming that an antisense mechanism is probably responsible for the accumulation in tumor cells in culture of radiolabeled DNAs with base sequences antisense to target messenger RNAs (mRNAs). That an increased accumulations of these DNAs compared to control DNAs has now been seen in a substantial number of tumor cell types and mRNA targets largely eliminates any possibility of an aptameric effect being responsible for these specific accumulations. In addition, the number of antisense DNAs accumulating specifically in cells in culture has been shown to be orders of magnitude larger than that expected on the basis of steady state mRNA levels. Thus, two of the main concerns regarding antisense targeted, namely that the mechanism of localization may not be attributed to antisense and that the degree of accumulation will be impractically low for imaging, have been addressed in recent research. The remaining obstacle to successful targeting may be delivery. This review will provide a brief review of recent results, primarily from the laboratory of one of the authors (DJH), obtained in tissue culture in studies of antisense targeting and will conclude with several suggestions for future approaches.
Key wordsantisense cells technetium-99m
Unable to display preview. Download preview PDF.
- 2.Hnatowich DJ. Antisense and Nuclear Medicine. Where are we now?Cancer Biotherapy and Radiopharmaceuticals 2000; 15:447–4577.Google Scholar
- 3.Crook ST. Basic principles of antisense technology. Ed. Crook ST.In Antisense Drug Technology. Principles, Strategies, and Applications. New York; Marcel Dekker, Inc., 2001: 14.Google Scholar
- 4.Henry CM. High hopes for RNA Interference.Chem Engineering News 2003; 22 December.Google Scholar
- 5.Glaser V. Antisense drugs hope to enter the mainstream.Genetic Engineering News 2003; 15 October.Google Scholar
- 12.Nakamura K, Liu G, Zhang Y, Kubo A, Hnatowich DJ. Antisense targeting of P-glycoprotein MDR expression in tissue culture, [abstract]J Nucl Med 2003; 44(Suppl):p304.Google Scholar
- 19.Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperi- toneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice.Clin Cancer Res 2001; 7:3600–36011.Google Scholar
- 23.Zhang Y, Liu C, Zhang S, He J, Rusckowski M, Hnatowich DJ. Improved antisense vs. control accumulations in cells using99mTc labeled morpholinos as alternatives to labeled DNAs when incubated naked, [abstract]J Nucl Med 2002; 43 (Suppl): 138.Google Scholar